Naoki Kaneko Selected Research

naquotinib

1/2020	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
1/2019	Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoki Kaneko Research Topics

Disease

20	Neoplasms (Cancer) 01/2020 - 04/2009
7	Aneurysm (Aneurysms) 10/2022 - 07/2017
4	Intracranial Aneurysm (Cerebral Aneurysm) 01/2021 - 08/2016
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 06/2011
4	Lymphoma (Lymphomas) 06/2011 - 03/2006
3	Immunoglobulin G4-Related Disease 01/2022 - 01/2020
3	Ischemic Stroke 01/2021 - 03/2019
3	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2014
3	Squamous Cell Carcinoma of Head and Neck 10/2019 - 05/2015
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2018 - 06/2011
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017 - 06/2016
3	Ischemia 10/2014 - 01/2012
3	Body Weight (Weight, Body) 04/2014 - 08/2011
2	Pathologic Constriction (Stenosis) 10/2022 - 01/2021
2	Fibrosis (Cirrhosis) 01/2022 - 10/2021
2	Kimura Disease 01/2022 - 12/2019
2	COVID-19 01/2022 - 01/2021
2	Rupture 01/2021 - 03/2018
2	Stroke (Strokes) 01/2021 - 01/2021
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2019 - 10/2017
2	Breast Neoplasms (Breast Cancer) 09/2018 - 09/2011
2	Renal Cell Carcinoma (Grawitz Tumor) 05/2013 - 08/2008
2	Triple Negative Breast Neoplasms 01/2013 - 09/2011
2	Long QT Syndrome 01/2011 - 01/2011
2	Cardiac Arrhythmias (Arrythmia) 01/2011 - 01/2011
2	Premature Cardiac Complexes (Extrasystoles) 01/2011 - 01/2011
2	Atrioventricular Block 01/2011 - 01/2011
1	Urticaria (Hives) 01/2022
1	Anaphylaxis (Anaphylactic Shock) 01/2022
1	Amyloidosis 01/2022
1	Egg Hypersensitivity (Egg Allergy) 01/2022
1	False Aneurysm (Pseudoaneurysm) 01/2022
1	Dyspnea (Shortness of Breath) 01/2022
1	Respiratory Sounds (Crackle) 01/2022
1	Inflammation (Inflammations) 10/2021
1	Vascular Remodeling 01/2021
1	Multi-centric Castleman's Disease 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Thrombophilia 01/2021
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021
1	Cognitive Dysfunction 01/2020

Drug/Important Bio-Agent (IBA)

10	SurvivinIBA 12/2018 - 06/2011
10	sepantroniumIBA 09/2018 - 06/2011
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2006
4	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2014
3	CytokinesIBA 01/2022 - 05/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2011
3	Rituximab (Mabthera)FDA Link 01/2020 - 10/2012
2	Immunoglobulin E (IgE)IBA 01/2022 - 12/2019
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	EnzymesIBA 01/2020 - 05/2013
2	naquotinibIBA 01/2020 - 01/2019
2	gilteritinibIBA 04/2019 - 10/2017
2	Neuroprotective AgentsIBA 12/2018 - 01/2012
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2016 - 06/2016
2	Parathyroid Hormone-Related ProteinIBA 07/2016 - 06/2016
2	Hormones (Hormone)IBA 06/2016 - 01/2012
2	Tumor Biomarkers (Tumor Markers)IBA 05/2013 - 05/2011
2	Galectin 1 (LGALS1)IBA 05/2013 - 05/2011
2	Docetaxel (Taxotere)FDA Link 01/2013 - 08/2011
2	Sotalol (Sotalol Hydrochloride)FDA LinkGeneric 01/2011 - 01/2011
2	Histidine (L-Histidine)FDA Link 06/2009 - 05/2009
2	Antigen Receptors (Antigen Receptor)IBA 05/2009 - 04/2009
1	Apolipoproteins E (ApoE)IBA 01/2022
1	GelatinIBA 01/2022
1	NanogelsIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Amyloid beta-PeptidesIBA 01/2022
1	DeodorantsIBA 01/2022
1	ChloridesIBA 01/2022
1	SilicatesIBA 01/2022
1	Biocompatible Materials (Biomaterials)IBA 01/2022
1	Interleukin-13IBA 01/2022
1	Granzymes (Granzyme)IBA 01/2022
1	stachybocin AIBA 01/2022
1	Muramidase (Lysozyme)IBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2021
1	Protein SIBA 10/2021
1	c-Mer Tyrosine KinaseIBA 10/2021
1	LigandsIBA 10/2021
1	Tyrosine (L-Tyrosine)FDA Link 10/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Interleukin-1 (Interleukin 1)IBA 01/2021
1	Phenobarbital (Luminal)FDA Link 01/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2020
1	Chemotactic FactorsIBA 01/2020
1	CollagenIBA 01/2020

Therapy/Procedure

8	Therapeutics 01/2021 - 06/2011
4	Drug Therapy (Chemotherapy) 04/2019 - 08/2008
3	Thrombectomy 01/2021 - 03/2019
3	Stents 01/2021 - 03/2019
3	Oral Administration 10/2017 - 01/2011
2	Catheters 10/2022 - 01/2022
2	Punctures 01/2022 - 01/2021
2	Radiotherapy 11/2020 - 08/2008
2	Surgical Instruments (Clip) 10/2018 - 07/2017
1	Endovascular Procedures 01/2021